r use through 10/31/99. OMB 0651-0031 e: U.S. DEPARTMENT OF COMMERCE

s it contains a valid OMB control number

Patent and Tradem sons are required to respond to a collection of informatic Under the Paperwork Reduction Act of 1995

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

of 3 Sheet

Complete if Known **Application Number** 07/18/2001 Filing Date R. Rex Denton First Named Inventor Group Art Unit Examiner Name MWH-008US Attorney Docket Number

				U.S. PATENT DOCL	JMENTS	Pages, Columns, Lines,
xaminer nitials*	Cite No.1	U.S. Patent I	Ocument Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear col. 5, line 10 - col. 9, line 13
	AA	5,625,039	A	Washida et al.	04/29/1997	col. 6, line 49-col.7, line 2; col 13, line 1
	AB	5,770,396	A	Kinet et al.	06/23/1998	col 16, line 21; col 26, line 21-col. 27
	700	3,773,222				line 3; col. 30, line 44 - col. 31, line
						(1, -s1 22 line 41-54
	-			·		61; col. 32, line 41-54
	<del> </del> -					
		<del>                                     </del>			_	
	<del> </del>		- T.			
	+					
	+					
	+					
	+					
	+					
	+-	1				
	+	+				
	+	+				
	+-	<del></del>				

				FOR	EIGN PATENT DOCUMENT	<u>s</u>	Pages, Columns, Lines,	Т
Examiner Initials*	Cite No.1	Office	Foreign Patent Do	cument  Kind Code <sup>5</sup> (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	T6
IIIIIIIII			95/05481	A1	Isis Innovation Limited	02/23/1995	pages 7-16	+
								1
<u> </u>		-						十
								$\bot$
<b> </b>		┼						+
								Ŧ
<u> </u>	<del>                                     </del>	┼	ļ					_

		Date	
Examiner		Considered	·
Signature	A situation is in conformance with MPER	609. Draw line	through citation if not in conformance and

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Please	type	a plus	sign (+	) inside	this	box	_
--------	------	--------	---------	----------	------	-----	---

Substitute for form 1449B/PTO

Appro Patent and Tradema

PTO/SB/08B (10-96) use through 10/31/99. OMB 0651-0031 U.S. DEPARTMENT OF COMMERCE it contains a valid OMB control number.

ons are required to respond to a collection of information Under the Paperwork Reduction Act of 1995. Complete if Known

Complete II Known					
Application Number					
Filing Date	07/18/2001				
First Named Inventor	R. Rex Denton				

(use as many sheets as necessary) of 🖪

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Group Art Unit **Examiner Name** Attorney Docket Number MWH-008US

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), Cite Examiner publisher, city and/or country where published. No.1 Initials ADAMCZEWSKI, M. ET AL.., "Expression and Biological Effects of High Levels of Serum IgE in BA Epsilon Heavy Chain Transgenic Mice.," European Journal of Immunology, Vol. 21, p. 617-626, (1991) COX, H.E. ET AL., , "Association of Atopic Dermatitis to the Beta Subunit of the High Affinity BB Immunoglobulin E Receptor," British Journal of Dermatology, Vol. 138, p. 182-187, (1998). DIAZ-SANCHEZ, A.S. ET AL., "Regulation of the Expression of Distinct Human Secreted IgE Proteins Prodouced by Alternative RNA Splicing" in Immunological Intervention Strategies in Allergy Biochemical Society Transactions, Vol. 25, (No. 25) p. 383-387, (1997). DICKSON, PHILLIP W. ET AL., "Mutational Analysis of the High Affinity Immunoglobulin BD E Receptor B Subunit Gene in Asthma," Thorax, Vol. 54, p. 409-412, (1999). HILL AND COOKSON, "A New Variant of the B Subunit of the High-Affinitiv Receptor for Immunoglobulin E (FCER1-B E237G): Associations with Measures of Atopy and Bronchial BE Hyper-Responsiveness," Human Molecular Genetics, Vol. 5, p. 959-962, (1996). HIZAWA, NOBUYUKI ET AL., "A Common FCER1B Gene Promoter Polymorphism Influences Total Serus IgE Levels in a Japanese Population," Am J Respi Crit Care Med, Vol. 161, p. 906-909, (2000). KINET, J.P. ET AL., "Isolation and Characterization of cDNA's Coding for the B-Subunit of the High-Affinity Receptor for Immunoglobulin E. Proceedings of the National Academy of BG Sciences," PNAS, Vol. 85, p. 6483-6487, (1998). PALMER, L.J. ET AL., "FCER1-B Polymorpohisms and Total Serum 1gE Levels in Endemically Parasitized Australian Aborigines," Am. J. Hum. Genet., Vol. 61, p. 182-188, BHI(1997). RIVERA, J. ET AL.., "Studies with a Monoclonal Antibody to the BSubunit of the Receptor with High Affinitiy for Immunglobulin E," Molecular Immunology, Vol. 25 (No. 7), p. 547-661, BI (1988). SATO, T. ET AL., "A New Method for Studying the Binding of Human IgE to CD23 and the Inhibition of this Binding," Journal of Immunological Methods, Vol. 209, p. 59-66, (1997).BJSHIRAKAWA, TARO ET AL., "Association between Atopy and Variants of the B Subunit of the High-Affinity Immunoglobulin E Receptor," Nature Genetics, Vol. 7, p. BK 125-130, (1994).

	Date
Examiner	Considered
Signature	the state of the conformance and no

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Please	tvoe a	olus	sian	(+) inside	this	box	_
1 10030	type a	Pius	aigii	(1) 1113100	tr no	OOA	

Under the Paperwork Reduction Act of 1995

Sheet

Patent and Tradema

PTO/SB/08B (10-96) use through 10/31/99. OMB 0651-0031 E: U.S. DEPARTMENT OF COMMERCE

Approx it contains a valid OMB control number. ons are required to respond to a collection of information

Substitute for form 1449B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) of 5

Complete if Known					
Application Number					
Filing Date	07/18/2001				
First Named Inventor	R. Rex Denton				
Group Art Unit					
Examiner Name					
Attorney Docket Number	MWH-008IIS				

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the T2 xeminer Cite item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), No.1 publisher, city and/or country where published. SHIRAKAWA, T. ET AL., "Association between Atopic Asthma and a Coding Variant of FCER1B in a Japanese Popoulation," Human Molecular Genetics, Vol. 5, p. 1129-1130, (1996). BLWITTHUHN B. A.. ET AL., "Isolation and Characterization of the Rat B-Subunit Gene of the High Affinity Receptor for Immunoglobulin E.," Molecular Immunology, Vol. 33, (No. 10), p. BM 881-890

		_
Examiner	Date	
Signature	Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.